Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Sep 30;13(9):1515-1516.
doi: 10.21037/tp-24-249. Epub 2024 Sep 26.

Assessment of the efficacy of vosoritide therapy in children with achondroplasia in clinical trials

Wiktoria Wrobel  1 , Iwona Ben-Skowronek  1
Affiliations
Editorial

Assessment of the efficacy of vosoritide therapy in children with achondroplasia in clinical trials

Wiktoria Wrobel et al. Transl Pediatr. .
No abstract available

Keywords: Achondroplasia; growth; treatment; vosoritide.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-24-249/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Hosny GA. Limb lengthening history, evolution, complications and current concepts. J Orthop Traumatol 2020;21:3. 10.1186/s10195-019-0541-3 - DOI - PMC - PubMed
    1. Simran S. KDS, Dushantrao SC, et al. Vosoritide, a miracle drug, covering unmet need in achondroplasia: A regulatory update. Intractable Rare Dis Res 2023;12:257-61. 10.5582/irdr.2023.01055 - DOI - PMC - PubMed
    1. Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet 2020;396:684-92. Erratum in: Lancet 2020;396:1070.10.1016/S0140-6736(20)31541-5 - DOI - PubMed
    1. Savarirayan R, Wilcox WR, Harmatz P, et al. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Child Adolesc Health 2024;8:40-50. 10.1016/S2352-4642(23)00265-1 - DOI - PubMed

LinkOut - more resources